Abdul H El Chafic1, Janak N Shah2, Chris Hamerski3, Kenneth F Binmoeller3, Shayan Irani4, Theodore W James5, Todd H Baron5, Jose Nieto6, Ricardo V Romero2, John A Evans2, Michel Kahaleh7. 1. Ochsner Medical Center, 1514 Jefferson Hwy, New Orleans, LA, 70121, USA. abdulchafic@gmail.com. 2. Ochsner Medical Center, 1514 Jefferson Hwy, New Orleans, LA, 70121, USA. 3. California Pacific Medical Center, San Francisco, CA, USA. 4. Virginia Mason Medical Center, Seattle, WA, USA. 5. University of North Carolina, Chapel Hill, NC, USA. 6. Borland-Groover Clinic, Jacksonville, FL, USA. 7. Weill Cornell Medicine, New York, NY, USA.
Abstract
BACKGROUND AND AIMS: EUS-guided biliary drainage has emerged as a technique to enable endobiliary drainage in failed ERCP. A newer model, lumen-apposing metal stents (LAMS), with a cautery-enhanced delivery system became available in the USA in late 2015. This cautery-tipped version may facilitate EUS-guided choledochoduodenostomy (EUS-CD), but data using this model are lacking. METHODS: We reviewed outcomes of attempted EUS-CD using cautery-enhanced LAMS from 6, US centers. The following data were collected: patient and procedure details, technical success, adverse events, clinical success (resolution of jaundice or improvement in bilirubin > 50%), and biliary re-interventions. RESULTS: EUS-CD was attempted in 67 patients (mean age 68.8) with malignant obstruction after failed ERCP between September 2015 and April 2018. EUS-CD was technically successful in 64 (95.5%). A plastic or metal stent was inserted through the lumen of the deployed LAMS in 50 of 64 (78.1%) patients to maintain a non-perpendicular LAMS axis into the bile duct. Adverse events occurred in 4 (6.3%) and included: abdominal pain (n = 2), peritonitis that responded to antibiotics (n = 1), and bleeding requiring transfusion (n = 1). Among 40 patients with follow-up of > 4 weeks, clinical success was achieved in 100%. Biliary re-interventions for obstruction were needed in 7(17.5%), in 3 of 6 (50.0%) that underwent EUS-CD with LAMS alone versus 4 of 34 (5%) with LAMS plus an axis-orienting stent (p = 0.02). CONCLUSION: EUS-CD using LAMS with cautery-enhanced delivery systems has high technical and clinical success rates, with a low rate of adverse events. Inserting an axis-orienting stent through the lumen of the LAMS may reduce the need for biliary re-interventions.
BACKGROUND AND AIMS: EUS-guided biliary drainage has emerged as a technique to enable endobiliary drainage in failed ERCP. A newer model, lumen-apposing metal stents (LAMS), with a cautery-enhanced delivery system became available in the USA in late 2015. This cautery-tipped version may facilitate EUS-guided choledochoduodenostomy (EUS-CD), but data using this model are lacking. METHODS: We reviewed outcomes of attempted EUS-CD using cautery-enhanced LAMS from 6, US centers. The following data were collected: patient and procedure details, technical success, adverse events, clinical success (resolution of jaundice or improvement in bilirubin > 50%), and biliary re-interventions. RESULTS:EUS-CD was attempted in 67 patients (mean age 68.8) with malignant obstruction after failed ERCP between September 2015 and April 2018. EUS-CD was technically successful in 64 (95.5%). A plastic or metal stent was inserted through the lumen of the deployed LAMS in 50 of 64 (78.1%) patients to maintain a non-perpendicular LAMS axis into the bile duct. Adverse events occurred in 4 (6.3%) and included: abdominal pain (n = 2), peritonitis that responded to antibiotics (n = 1), and bleeding requiring transfusion (n = 1). Among 40 patients with follow-up of > 4 weeks, clinical success was achieved in 100%. Biliary re-interventions for obstruction were needed in 7(17.5%), in 3 of 6 (50.0%) that underwent EUS-CD with LAMS alone versus 4 of 34 (5%) with LAMS plus an axis-orienting stent (p = 0.02). CONCLUSION:EUS-CD using LAMS with cautery-enhanced delivery systems has high technical and clinical success rates, with a low rate of adverse events. Inserting an axis-orienting stent through the lumen of the LAMS may reduce the need for biliary re-interventions.
Authors: C Fabbri; C Luigiano; L Fuccio; A M Polifemo; F Ferrara; S Ghersi; M Bassi; P Billi; A Maimone; V Cennamo; M Masetti; E Jovine; N D'Imperio Journal: Endoscopy Date: 2011-01-26 Impact factor: 10.093
Authors: Marina de Benito Sanz; Rodrigo Nájera-Muñoz; Carlos de la Serna-Higuera; Esteban Fuentes-Valenzuela; Ignacio Fanjul; Carlos Chavarría; Francisco Javier García-Alonso; Ramón Sanchez-Ocana; Ana Yaiza Carbajo; Sergio Bazaga; Manuel Perez-Miranda Journal: Surg Endosc Date: 2020-11-30 Impact factor: 4.584
Authors: Albert Garcia-Sumalla; Carme Loras; Vicente Sanchiz; Rafael Pedraza Sanz; Enrique Vazquez-Sequeiros; Jose Ramon Aparicio; Carlos de la Serna-Higuera; Daniel Luna-Rodriguez; Xavier Andujar; María Capilla; Tatiana Barberá; Jose Ramon Foruny-Olcina; Belen Martínez; Miguel Dura; Silvia Salord; Berta Laquente; Cristian Tebe; Sebastia Videla; Manuel Perez-Miranda; Joan B Gornals Journal: Trials Date: 2022-02-25 Impact factor: 2.728
Authors: Tarek Sawas; Natashay J Bailey; Kit Ying Kitty Au Yeung; Theodore W James; Sumana Reddy; Chad J Fleming; Neil B Marya; Andrew C Storm; Barham K Abu Dayyeh; Bret T Petersen; John A Martin; Michael J Levy; Todd H Baron; Anthony Yuen Bun Teoh; Vinay Chandrasekhara Journal: Endosc Ultrasound Date: 2022 May-Jun Impact factor: 5.275